Use and abuse of the controlled clinical trial

Bulletin of the NYU Hospital for Joint Diseases

Volumn 65, Issue 2, 2007, Pages 132-134

  Yazici, Hasan ^a,b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ROFECOXIB;

ARTICLE; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HYPOTHESIS; PUBLISHING; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; HUMAN; METHODOLOGY; STANDARD;

HUMANS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS;

EID: 34548440203     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Kramer BS, Wilentz J, Alexander D. Getting it right: Being smarter about clinical trials. PloS Medicine 2006;3:756-61.
2. Coulter HL. The Controlled Clinical Trial: An Analysis. Washington, DC: Center for Empirical Medicine, 1991.
3. Magee B. Scientific method the traditional view and Popper's view. In: Popper. Fontana: London, 1982, pp. 18-34.
4. Fries JF, Krishnan E. Equipoise, design bias, and randomized controlled trials: The elusive ethics of new drug development. Arthritis Res Ther. 2004;6:250-5.
5. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol. 2003;30:1138-46.
6. Gogus F, Yazici Y, Yazici H. Inclusion criteria as widely used for rheumatoid arthritis clinical trials: Patient eligibility in a Turkish cohort. Clin Exp Rheumatol. 2005;23:681-4.
7. Cleophas TJ, Zwinderman AH. Limitations of randomized clinical trials, proposed alternative designs. Clin Chem Lab Med. 2000;38:1217-23.
8. Pincus T. Guidelines for monitoring of methotrexate: "Evidence-based medicine" outside of clinical trials. Arthritis Rheum. 2003;48:2706-9.
9. Anonymous. Merck Announces Voluntary Worldwide Withdrawal of VIOXX®. http://www.vioxx.com/rofecoxib/vioxx/consumer/voluntary_withdrawl_statement.jsp. Accessed February 6, 200707.
10. Kessler DA. MEDWatch: The new FDA medical products reporting program. Am J Hosp Pharm. 1993;50:1151-2.
11. Taylor WJ, Weatherhall M. What are open-label extension studies for? J Rheumatol. 2006;33:642-3.
12. Yazici H. Is the STAR trial really a safety trial? J Rheumatol. 2004;31:2528.